Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

An experimental gene-editing drug, VERVE-102, showed a 62% reduction in LDL cholesterol in a Phase I trial with 35 patients, with no serious adverse events reported. The treatment demonstrated sustained effectiveness over 18 months, though a temporary mild liver enzyme increase was observed.